Author

Violet Korutaro

Institution: Baylor College of Medicine Children’s Foundation

Observed institutions: Mulago Hospital, Baylor College of Medicine Children’s Foundation

ORCID: 0000-0003-1741-4771

Observed ORCID: 0000-0003-1741-4771

OpenAlex ID: A5048941667

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

2021 · Shahin Lockman, Sean S Brummel, et al. · The Lancet · 176

Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa

2020 · Lynda Stranix-Chibanda, Peter L Anderson, et al. · Clinical Infectious Diseases · 74

PDF

Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial

2023 · Lameck Chinula, Lauren Ziemba, et al. · The Lancet HIV · 37

PDF

HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study

2023 · Deborah Persaud, Yvonne Bryson, et al. · The Lancet HIV · 33

PDF

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

2025 · Carolyn Bolton Moore, Kristin Baltrusaitis, et al. · The Lancet HIV · 18

PDF

ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study

2025 · Deborah Persaud, Anne Coletti, et al. · The Lancet HIV · 15

PDF

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV

2018 · Felicity C Fitzgerald, Edouard Lhomme, et al. · The Journal of Infectious Diseases · 15

PDF

Prospective Long-term Outcomes of a Cohort of Ugandan Children With Laboratory Monitoring During Antiretroviral Therapy

2012 · Adeodata Kekitiinwa, Alice R. Asiimwe, et al. · The Pediatric Infectious Disease Journal · 15

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study

2026 · Aditya H Gaur, Kristin Baltrusaitis, et al. · The Lancet HIV · 8

PDF

Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy

2024 · Ahizechukwu C Eke, Sean S Brummel, et al. · Clinical Infectious Diseases · 6

PDF

Brief Report: Characterizing HIV Drug Resistance in Cases of Vertical Transmission in the VESTED Randomized Antiretroviral Treatment Trial

2024 · Marley D. Bishop, Violet Korutaro, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 6

PDF

Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial

2026 · Elizabeth D Lowenthal, Jennifer Chapman, et al. · The Lancet HIV · 4

PDF

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2

Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet · 1

Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial

2026 · Carolyn Bolton Moore, Kristin Baltrusaitis, et al. · The Lancet Child & Adolescent Health

Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum

2026 · Benjamin H. Chi, Deborah Kacanek, et al. · AIDS

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED

2025 · Tk Nguyen, Jung-Woo Chae, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes

PDF

A clinical research site pharmacy for the division of AIDS sponsored clinical trials in a low middle income country

2024 · Rogers Sekabira, Godwin Murungi, et al. · International Journal of Scientific Reports

PDF

Works count: 18

Citation count: 408

H-index: 8

I10-index: 8